 Naltrexone
"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.549.686.750.550 D03.605.497.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
Celupan- Celupan
- Lacer Brand of Naltrexone Hydrochloride
ReVia- ReVia
- Du Pont Brand of Naltrexone Hydrochloride
- Lamepro Brand of Naltrexone Hydrochloride
- United Drug Brand of Naltrexone Hydrochloride
- Nemexin
- Orphan Brand of Naltrexone Hydrochloride
- Schering-Plough Brand of Naltrexone Hydrochloride
- Schering Plough Brand of Naltrexone Hydrochloride
- Bristol-Myers Squibb Brand of Naltrexone Hydrochloride
- Bristol Myers Squibb Brand of Naltrexone Hydrochloride
- Nalorex
Antaxone- Antaxone
- Pharmazam Brand of Naltrexone Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 1 | 1 | | 1987 | 1 | 0 | 1 | | 1989 | 1 | 0 | 1 | | 1991 | 0 | 1 | 1 | | 1992 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Krupitsky EM, Blokhina EA, Zvartau EE, Verbitskaya VE, Bushara EM, Tiurina AA, Palatkin VY, Yaroslavtseva TS, Burakov AM, Masalov DV, Romanova TN, Grininko AY, Sinha R, Kosten T. [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115(10):39-46.
-
Haile CN, Kosten TA, Kosten TR. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am J Drug Alcohol Abuse. 2008; 34(4):355-81.
-
Kosten TA, Haile CN, Jatlow P. Naltrexone and morphine alter the discrimination and plasma levels of ethanol. Behav Pharmacol. 1999 Feb; 10(1):1-13.
-
Boyle AE, Stewart RB, Macenski MJ, Spiga R, Johnson BA, Meisch RA. Effects of acute and chronic doses of naltrexone on ethanol self-administration in rhesus monkeys. Alcohol Clin Exp Res. 1998 Apr; 22(2):359-66.
-
Kosten T, Silverman DG, Fleming J, Kosten TA, Gawin FH, Compton M, Jatlow P, Byck R. Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol Psychiatry. 1992 Sep 15; 32(6):543-8.
-
Kosten TA, Kosten TR. Pharmacological blocking agents for treating substance abuse. J Nerv Ment Dis. 1991 Oct; 179(10):583-92.
-
Murray MJ, Offord KP, Yaksh TL. Physiologic and plasma hormone correlates of survival in endotoxic dogs: effects of opiate antagonists. Crit Care Med. 1989 Jan; 17(1):39-47.
-
Kleber HD, Topazian M, Gaspari J, Riordan CE, Kosten T. Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. Am J Drug Alcohol Abuse. 1987; 13(1-2):1-17.
-
Stickney JL, Eikenburg DC. Peripheral sympatholytic effects of 1-alpha-acetylmethadol. J Cardiovasc Pharmacol. 1981 Mar-Apr; 3(2):369-80.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|